Picture loading failed.

Anti-TNFA;ALB therapeutic antibody (Pre-made Ozoralizumab biosimilar,Bispecific Single Domains (VH-VH'-VH)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Ozoralizumab is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-419-1mg 1mg Inquiry
GMP-Bios-ab-419-10mg 10mg Inquiry
GMP-Bios-ab-419-100mg 100mg Inquiry
GMP-Bios-ab-419-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-TNFA;ALB therapeutic antibody (Pre-made Ozoralizumab biosimilar,Bispecific Single Domains (VH-VH'-VH))
INN Name Ozoralizumab
FormatBispecific Single Domains (VH-VH'-VH)
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI Structure5m2j:D;None
Year Proposed2011
Year Recommended2012
CompaniesAblynx;Eddingpharm;Pfizer;Taisho Pharmaceutical
Conditions Approvedna
Conditions ActiveRheumatoid arthritis
Conditions DiscontinuedAnkylosing spondylitis;Crohn's disease;Psoriatic arthritis
Development TechNanobody Technology